The Regeneration Stack
Multi-peptide recovery blend combining BPC-157 and TB-500 class compounds.
Mechanism of Action
Bioregulator compound with targeted biochemical activity.
Evidence Chain
The Regeneration Stack
COMPOUND
1 Research Goal
• Injury & Wound Healing
Evidence Strength
1 article sourced
Knowledge Graph
(2 connections)Overview
The Regeneration Stack is a multi-peptide recovery blend combining BPC-157 and TB-500 class compounds, designed to provide comprehensive support for tissue repair and regeneration research. This stack leverages the complementary healing mechanisms of these two well-studied peptides, which target different aspects of the tissue repair process — from angiogenesis and cell migration to extracellular matrix remodeling and inflammation modulation.
Mechanism of Action
The Regeneration Stack combines two complementary tissue-repair peptides. BPC-157 promotes healing through VEGF upregulation, angiogenesis, fibroblast migration, and modulation of the nitric oxide and prostaglandin systems. TB-500 (thymosin beta-4 fragment) promotes healing through actin-binding and regulation of cell migration, VEGF expression, and anti-inflammatory effects. The combination targets multiple aspects of tissue repair simultaneously — BPC-157 focusing on vascular and cellular repair mechanisms, TB-500 on structural and migratory aspects — potentially producing synergistic healing effects.
Research Highlights
Individual component peptides have demonstrated remarkable tissue healing properties in preclinical research. BPC-157 has shown efficacy in healing tendons, ligaments, muscles, skin, and gastrointestinal tissue. TB-500 has demonstrated efficacy in wound healing, cardiac repair, and tissue remodeling. The combination is designed to leverage complementary mechanisms for comprehensive regeneration support. Research on the specific combination is limited, with most data derived from individual component studies.
Dosage & Administration
As a research blend, dosing protocols are not standardized. Individual components have been used at doses of 250-500 mcg (BPC-157) and 2-5 mg (TB-500) in research. For research use only (RUO).
Safety Profile
Individual components have demonstrated favorable safety profiles in preclinical studies. The combination may produce additive or synergistic effects. Full safety characterization of the combination is pending. Not approved by the FDA for any indication.
References
Sikiric P, et al. BPC-157 and tissue healing. Curr Pharm Des. 2018. Goldstein AL, et al. Thymosin beta-4 and tissue repair. Ann N Y Acad Sci. 2010. Refer to individual component references. All content is for educational and research purposes only.
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.